QuidelOrtho Corp.
- QDEL · Nasdaq
- In Vitro & In Vivo Diagnostic Substances
- San Diego, CA
- 6,500 employees
- CIK 0001906324
Updated from SEC filings through
Top things to know
Executives
-
Brian J. Blaser President and Chief Executive Officer of QuidelOrtho 8-K, 2026-11-03
-
Micah W. Young Chief Financial Officer 4, 2026-07-16 - Micah Young Chief Financial Officer 8-K, 2026-06-23
- Joseph M. Busky Chief Financial Officer 4, 2026-03-31
- Ronald Lee Bowman Chief Human Resources Officer 4, 2026-09-17
- Philip D. McLellan Chief Operations Officer 4, 2026-04-28
What leadership is saying
“The underlying performance of our Labs and Immunohematology businesses remained solid in the third quarter, supported by the strength and durability of our customer relationships and our large global installed base”
Earnings press release (8-K Ex. 99.1), filed November 3, 2026
QuidelOrtho Corp is a U.S. public company in in vitro & in vivo diagnostic substances (SIC 2835), headquartered in San Diego, CA. It trades as QDEL on Nasdaq. Revenue was $2.7B in the fiscal year ending December 28, 2025, -1.9% from the year before. It reported about 6,500 employees. Brian J. Blaser is President and Chief Executive Officer of QuidelOrtho.
Five-year financials
| Metric | FY2025 | FY2024 | FY2023 | FY2023 | FY2022 |
|---|---|---|---|---|---|
| Revenue | $2.7B 10-K, 2026-02-19 | $2.8B 10-K, 2026-02-19 | $3.0B 10-K, 2026-02-19 | $3.3B 10-K, 2025-02-27 | $1.7B 10-K/A, 2024-08-01 |
| Operating income | -$919M 10-K, 2026-02-19 | -$2.0B 10-K, 2026-02-19 | $139M 10-K, 2026-02-19 | $844M 10-K, 2025-02-27 | $906M 10-K/A, 2024-08-01 |
| SG&A | $746M 10-K, 2026-02-19 | $767M 10-K, 2026-02-19 | $763M 10-K, 2026-02-19 | $621M 10-K, 2025-02-27 | $240M 10-K/A, 2024-08-01 |
| Net income | -$1.1B 10-K, 2026-02-19 | -$2.1B 10-K, 2026-02-19 | -$10.1M 10-K, 2026-02-19 | $549M 10-K, 2025-02-27 | $704M 10-K/A, 2024-08-01 |
Annual figures from XBRL in each company's own filings. Click a figure to open the filing. SG&A marked derived is general and administrative plus selling and marketing.
Leadership and board
| Name | Title | Source |
|---|---|---|
| Brian J. Blaser President and Chief Executive Officer at QuidelOrtho | President and Chief Executive Officer of QuidelOrtho | 8-K, 2026-11-03 |
| Evelyn S. Dilsaver | Board member (per proxy) bio: Former President and Chief Executive Officer of Charles Schwab Investment Management | DEF 14A, 2026-04-27 |
| John R. Chiminski | Board member (per proxy) bio: Former Executive Chair, President and Chief Executive Officer of Catalent, Inc. | DEF 14A, 2026-04-27 |
| Kenneth J. Widder, M.D. | Board member (per proxy) bio: Former Chief Executive Officer of Sydnexis, Inc. | DEF 14A, 2026-04-27 |
| R. Scott Huennekens | Board member (per proxy) bio: Former Chairman, President and Chief Executive Officer of Verb Surgical, Inc. | DEF 14A, 2026-04-27 |
| Micah W. Young | Chief Financial Officer | 4, 2026-07-16 |
| Micah Young | Chief Financial Officer | 8-K, 2026-06-23 |
| Ann D. Rhoads | Board member (per proxy) bio: Former Chief Financial Officer of Forty Seven, Inc. | DEF 14A, 2026-04-27 |
| Joseph M. Busky | Chief Financial Officer | 4, 2026-03-31 |
| Ronald Lee Bowman | Chief Human Resources Officer | 4, 2026-09-17 |
| Philip D. McLellan | Chief Operations Officer | 4, 2026-04-28 |
 Bryan M. Hanson Experienced Med Device Industry Leader | General Management & Portfolio Mgmt Expert | Driving Turnarounds & Rapid Performance Improvements | Global Multinationa | Named in proxy bio: Executive Vice President (“EVP”), Global Portfolio Management and Marketing | DEF 14A, 2026-04-27 |
 Jonathan P. Siegrist EVP R&D and CTO at QuidelOrtho | Named in proxy bio: EVP of R&D and Chief Technology Officer (“CTO”) | DEF 14A, 2026-04-27 |
 Lee Bowman | Named in proxy bio: Chief Human Resources Officer | DEF 14A, 2026-04-27 |
 Nathaniel B. Sisitsky Chief Legal Officer and Corporate Secretary at QuidelOrtho | Named in proxy bio: Chief Legal Officer (“CLO”) and Corporate Secretary | DEF 14A, 2026-04-27 |
| Edward L. Michael | Board member (per proxy) bio: Managing Partner and Co-founder of LionBird Ventures and former Executive Vice President, Diagnostics Products at Abbott Laboratories | DEF 14A, 2026-04-27 |
What QuidelOrtho Corp does
All references to “the Company,” “we,” “our” and “us” in this Annual Report refer to QuidelOrtho Corporation (“QuidelOrtho”) and its subsidiaries. References to “fiscal year ended 2025,” “fiscal year ended 2024” and “fiscal year ended 2023” in this Annual Report refer to the Company’s fiscal years ended December 28, 2025, December 29, 2024 and December 31, 2023, respectively. Refer to the Summary of Abbreviated Terms at the end of this Annual Report for definitions of terms used throughout this Annual Report.
Item 1. Business, 10-K for the year ending December 28, 2025
Shares and governance
| Shares outstanding | 68.6 million (as of October 28, 2026) | 10-Q, November 4, 2026 |
|---|---|---|
| Public float | $1.9B (as of June 27, 2025) | 10-K, February 19, 2026 |
| Reportable segments | 5 (period ending September 27, 2026) | 10-Q, November 4, 2026 |
| Latest proxy statement | Meeting June 16, 2026 (filed April 27, 2026) | DEF 14A, April 27, 2026 |
| Auditor | Kpmg LLP (Short Hills, New Jersey) | Latest 10-K |
Insider trades
Open-market buys and sales by officers and directors, from Forms 4 and 5. One row per filing.
| Date | Insider | Trade | Shares | Value | Source |
|---|---|---|---|---|---|
| February 13, 2026 | Brian J. Blaser President and CEO | Buy | 10,540 | $249K | Form 4, February 13, 2026 |
| February 13, 2026 | Joseph M. Busky Chief Financial Officer | Buy | 3,370 | $80K | Form 4, February 13, 2026 |
| February 13, 2026 | Matthew Strobeck Director | Buy | 10,000 | $240K | Form 4, February 13, 2026 |
| December 10, 2025 | Ann D. Rhoads Director | Buy | 750 | $21K | Form 4, December 10, 2025 |
| November 26, 2025 | Joseph D. Wilkins Jr. Director | Buy | 370 | $10K | Form 4, December 1, 2025 |
| November 25, 2025 | Kenneth J. Widder Director | Sale | 4,026 | $112K | Form 4, November 25, 2025 |
| November 24, 2025 | Joseph M. Busky Chief Financial Officer | Buy | 4,770 | $124K | Form 4, November 25, 2025 |
| November 21, 2025 | Mary Lake Ph D. Polan Director | Buy | 1,000 | $22K | Form 4, November 24, 2025 |
Recent 8-K events
- 8-K filed 2026-11-03
- Item 2.02 Results of operations and financial condition (earnings release)
- Item 5.02 Departure or appointment of directors or officers; compensation
- 8-K filed 2026-09-23
- Item 1.01 Entry into a material definitive agreement
- 8-K filed 2026-08-06
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2026-06-23
- Item 5.02 Departure or appointment of directors or officers; compensation
- Item 7.01 Regulation FD disclosure
- 8-K filed 2026-06-16
- Item 5.07 Submission of matters to a vote of security holders
- 8-K filed 2026-05-05
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2026-04-15
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2026-03-24
- Item 5.02 Departure or appointment of directors or officers; compensation
- Item 7.01 Regulation FD disclosure
- 8-K filed 2026-02-13
- Item 5.02 Departure or appointment of directors or officers; compensation
- 8-K filed 2026-02-11
- Item 2.02 Results of operations and financial condition (earnings release)
Frequently asked questions about QuidelOrtho Corp
- What does QuidelOrtho Corp do?
- In its own words, from Item 1 of its 10-K: "All references to “the Company,” “we,” “our” and “us” in this Annual Report refer to QuidelOrtho Corporation (“QuidelOrtho”) and its subsidiaries. References to “fiscal year ended 2025,” “fiscal year ended 2024” and “fiscal year ended 2023” in this Annual Report refer to the Company’s fiscal years ended December 28, 2025, December 29, 2024 and December 31, 2023, respectively. Refer to the Summary of Abbreviated Terms at the end of this Annual Report for definitions of terms used throughout this Annual Report."
- What is QuidelOrtho Corp's revenue?
- $2.7B for the fiscal year ending December 28, 2025, from its 10-K filed February 19, 2026.
- Is QuidelOrtho Corp profitable?
- QuidelOrtho Corp reported net income of -$1.1B for the fiscal year ending December 28, 2025.
- How many employees does QuidelOrtho Corp have?
- About 6,500 as of December 28, 2025, as stated in its annual report.
- Who is the CEO of QuidelOrtho Corp?
- Brian J. Blaser, President and Chief Executive Officer of QuidelOrtho, as named in a 8-K filed November 3, 2026.
- Who is the CFO of QuidelOrtho Corp?
- Micah W. Young, Chief Financial Officer, as named in a 4 filed July 16, 2026.
- Where is QuidelOrtho Corp headquartered?
- San Diego, CA.
- What is QuidelOrtho Corp's stock ticker?
- QDEL on Nasdaq.
- What industry is QuidelOrtho Corp in?
- In Vitro & In Vivo Diagnostic Substances, SIC code 2835.
- What is QuidelOrtho Corp's website?
- quidelortho.com.
- When does QuidelOrtho Corp report earnings next?
- February 4, 2027. Source: estimate_8k_pattern.
- Is QuidelOrtho Corp a public company?
- Yes. QuidelOrtho Corp files with the SEC under CIK 0001906324 and trades as QDEL.
- Who audits QuidelOrtho Corp?
- Kpmg LLP, Short Hills, New Jersey, as named in its latest annual report (10-K).
- How many shares of QuidelOrtho Corp are outstanding?
- 68.6 million shares as of October 28, 2026, from its 10-Q filed November 4, 2026.
- What is QuidelOrtho Corp's public float?
- $1.9B as of June 27, 2025, as reported on the cover of its 10-K filed February 19, 2026.
- How many business segments does QuidelOrtho Corp report?
- 5 reportable segments for the period ending September 27, 2026, from its 10-Q filed November 4, 2026.
- When is QuidelOrtho Corp's annual shareholder meeting?
- June 16, 2026, per its proxy statement (DEF 14A) filed April 27, 2026.
- Have QuidelOrtho Corp insiders traded stock recently?
- Since November 19, 2025, officers and directors reported 1 open-market sale worth about $112K and 8 purchases worth about $1.2M on Forms 4 and 5. The most recent: Brian J. Blaser (President and CEO) bought 10,540 shares on February 13, 2026.